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Abstract
Spinocerebellar ataxia type 14 (SCA14) is an autosomal, dominant 
neurodegenerative disorder caused by mutations in PKCγ. The objective of this 
study was to determine effects of PKCγ H101Y SCA14 mutation on Purkinje cells 
in the transgenic mouse. Results demonstrated that wild type PKCγ-like Purkinje 
cell localization of HA-tagged PKCγ H101Y mutant proteins, altered morphology 
and loss of Purkinje cells were observed in the PKCγ H101Y SCA14 transgenic 
mouse at four weeks of age. Failure of stereotypical clasping responses in the 
hind limbs of transgenic mice was also observed. Further, PKCγ H101Y SCA14 
mutation caused lack of total cellular PKCγ enzyme activity, loss of connexin 57
phosphorylation on serines, and activation of caspase-12 in the PKCγ H101Y 
SCA14 transgenic mouse. Results clearly demonstrate a need for PKCγ control 
of gap junctions for maintenance of Purkinje cells. This is the first transgenic 
mouse to our knowledge which models a human SCA14 mutation. 
Introduction
Spinocereballar ataxias (SCAs) are autosomal, heterogeneous, dominant 
neurodegenerative disorders. SCAs are classified at least into 27 types. 
Fourteen out of 27 SCAs are linked to particular gene mutations [1]. 
Spinocerebellar ataxia type 14 (SCA14) is caused by mutations in the PKCγ 
gene with onset age as early as three years [2-27]. SCA14 is a newly identified 
neurodegenerative disorder, the mechanistic aspects of this disease remain 
unknown.   
PKC is a family of phospholipid-dependent serine/threonine kinases that 
participates in many cellular functions.  PKCγ is a classical PKC, primarily found 
in the central and peripheral nervous systems. It is particularly abundant in 
cerebellar Purkinje cells and in hippocampal pyramidal cells [28]. SCA14 
mutations occur throughout the PKCγ gene from the regulatory to catalytic 
domains and also include a six-pair in-frame deletion and a splice site mutation in 
the C1B region, where most mutations occur [2-27]. Verbeek et al. [10] reported
that PKCγ SCA14 mutations have increased kinase activity and altered 
membrane targeting in kidney COS-7 cells with overexpression of SCA14 
mutants. No significant mutant protein aggregation is observed. However, Seki et 
al. reported that SCA14 mutants are susceptible to aggregation in the Chinese 
hamster ovary CHO-K1 [7]. These contradictory conclusions, by two separate 
groups, indicates that irrelevant cell lines, such as kidney COS-7 and Chinese 
hamster ovary CHO-K1, may not be appropriate in vitro cell systems to study the 
molecular mechanism of a neurodegenerative disorder, such as SCA14. 
Since SCA14 is rare and not fatal in most cases, it is difficult to investigate 
the pathogenesis due to lacking of human brain tissue [2]. Thus, it is critical to 
generate an animal model with SCA14 phenotype. In our lab, we have previously 
used well-characterized, hippocampal neuronal HT22 cells [6,29]. We have 
demonstrated that these mutant PKCγ’s cause a caspase-3 linked apoptosis in 
culture and PKCγ SCA14 mutants are not activated by an oxidative signal such 
as H2O2 when expressed in neuronal HT22 cells in culture [6]. Endogenous wild 
type PKC is negatively affected by the presence of the mutations (ie., a 
dominant effect). Here we reported the generation of the PKCγ H101Y SCA14 
transgenic mouse which expresses loss of Purkinje cells and neurological 
phenotype.
Materials and Methods
Generation of the transgenic mouse: The HA-tagged PKCγ H101Y mice were 
generated in a C57BL/6J background by the standard transgenic strategy. The 
experiments were done at the University of Missouri-Columbia Transgenic 
Animal Facility using the pronuclear injection method. Injected DNA fragments in 
a length of 3.14 kb consisted of the CMV promoter, PKCγ H101Y SCA14 mutant
with N-terminal HA tags, and a SV40 poly A terminus. Positive pups were 
confirmed by PCR using tail genomic DNA. Primers used for PCR screen were:
Primer 1. HAFOR, Tm= 68 C, 35 mers: 
5’ CC ATG TAC CCA TAC GAT GTT CCA GAT TAC GCT CTT 3’
Primer 2. SCAREV, Tm=70 C, 28 mers:
5’ GGT CGC AGA AGG TGG GAC TGC TGT AGC T 3’
Predicted PCR products were 403 bp in length containing the HA tag and a 
partial N-terminal portion of PKCγ H101Y SCA14 mutants.
Internal control primer pairs (ZP3-1 and ZP3-2) were used as a DNA quality 
control to amplify genomic DNA:
ZP3-1   CAG CTC TAC ATC ACC TGC CA
Zp3-2  CAC TGG GAA GAG ACA CTC AG
The predicted products were 500 bp. 
Western blot was performed to further confirm the positive generations using 
anti-HA antibody. Founders were mated with wild type C57BL/6J mice to create 
the next generation. After the 6th generation, mice from same littermates were 
used for studies. 
Mouse cerebellar slice culture: Cerebellar slice culture was modified from the 
previous reports [28, 30]. Briefly, after euthanization, sagittal cerebella were 
obtained immediately from the wild type and/or PKCγ H101Y transgenic mice at 
age of 4 weeks. The cerebellar slices were sectioned at 250 μm and cultured in 
serum-free BME medium supplemented with 2.5 mM glutamine, 5 mM glucose 
and 5 ng/mL nerve growth factor at 5 % CO2 in an incubator at 37 ˚C for up to 1 
hour. H2O2/oxidative stress treatments were conducted in the slice culture 
system. After that, slices were homogenized for further analyses.
Cell cultures: HT22 cells were cultured in DMEM (high glucose, 4.5 g/L) 
(Invitrogen, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, 
GA) and 50 μg/ml gentamicin, 0.05 U/ml penicillin, 50 μg/ml streptomycin, pH 7.4 
at 37 °C in an atmosphere of 95% air and 5% CO2.
Western blot and immunoprecipitation: Western blotting and 
immunoprecipitation were performed as described previously [4]. For 
immunoprecipitation assay, cells or tissue homogenates were lysed. After 8,000 
x g centrifugation for 15 min the supernatants are used for immunoprecipitation. 
Anti-HA antibody was purchased from Covance (Berkeley, CA), anti-PKCγ was
from BD Biosciences (San Jose, CA), anti-Cx57 was purchased from Diatheva 
(Italy), and antibodies against caspase-3, caspase-12, and α-tubulin were
purchased from Cell Signaling (Danvers, MD).
PKCγ enzyme activity assays: PKCγ enzyme activity was measured as 
previously described [4]. Briefly, equal protein amounts of cerebellar slice 
extracts from the wild type or PKC γ H101Y transgenic mice were incubated with 
PKC γ antisera at 4 °C for 4 h to immunoprecipitate endogenous wild type PKCγ
and/or H101Y mutants. Immunoprecipitated PKCγ and/or PKCγ H101Y-agarose 
bead complexes were recovered and incubated with PKC reaction mixture 
according to the manufacturer's instructions. The fluorescent phospho-PepTag 
peptides (phosphorylated by PKCγ and/or PKCγH101Y) were resolved by 0.8% 
agarose gel electrophoresis and visualized under UV light. The phosphorylated 
peptide bands were excised, and their fluorescence intensities were quantified by 
spectrophotometry at 570 nm.
Immunohistochemistry and confocal microscopy: To determine the Purkinje 
cell localization of PKCγ, PKC γ H101Y, and Cx57 in the wild type and transgenic 
mice, cerebellar tissues were fixed in 2 % paraformaldehyde and sagittally 
sectioned at 20 μm in thickness using a cryostat. The cerebellar sections were 
labeled with primary antisera including anti-Cx57, anti-HA, and/or anti-PKCγ for 
overnight at 4 ˚C. After washing in PBS, the slice sections were further incubated 
with secondary antisera with Alexa Fluor 568 or 488 conjugation for 2 hours at 
room temperature. Then Purkinje cell localization of desired proteins was 
determined using a Nikon C1 confocal microscope.
Light microscopy: For the Purkinje cell pathogenesis study, whole cerebellum
was fixed in 2% paraformaldehyde, 2.5% glutaraldehyde, 0.1 M cacodylate and 
then post–fixed in osmium tetroxide. Dehydration was in 70 % ethanol for 12 h, 
overnight with 100 % ethanol, and 12 h with 100 % acetone and finally 
embedding in epon resin at room temperature. Sagittal cerebellar sections were 
made with an ultramicrotome and thick sections (1 μm) were cut with a diamond 
knife and stained with 1% toluidine blue. Purkinje cell layers including soma and 
dentrites were viewed and images were captured by a Nikon light microscope. 
Tail suspension photography: Neurological dysfunction of transgenic mice was 
exhibited as hindlimb and/or forelimb clasping determined by tail suspension test 
[31, 32]. A tape was applied to the surface of the tail to set a metal clip which is 
anchored to the fixed lever. Mice first struggled to escape but sooner or later 
attained a posture of immobility. The response of each mouse to 1 min of vertical 
suspension from the tail was tested and photographed. Total 12 transgenic and 
12 wild type mice at 12 months of age were tested. Of this, over 90 % of the 
transgenic mice exhibited a clasping response as illustrated in Figure 1D.
Measurement of cell surface Cx57 gap junction plaques: HT22 cells were 
treated with 200 nM 12-O-tetradecanoylphorbol-13-acetate (TPA), 100 μM H2O2, 
or phosphate-buffered saline (PBS) for 30 min. Endogenous Cx57 gap junctions 
was determined as described previously [4]. Briefly, the cells were fixed with 
2.5 % paraformaldehyde for 5 min and labeled with anti-Cx57 overnight at 4 ˚C. 
After washing, the fixed cells were incubated with the secondary antibody with 
Alexa Fluor 568 conjugation. The cells were then examined using a Nikon 
confocal microscope. We photographed ten points per slide, three slides for each 
treatment. For quantitation, the cell surface Cx57 gap junctions from single cells 
in single sections in each image were counted. The number of gap junction 
plaques was expressed as mean ± SEM. 
Statistical analysis: The statistical analysis employed in this paper is the 
unpaired Student's t-Test. All analyses represent at least triplicate experiments. 
The level of significance (*) was considered at p ≤ 0.05. All data are mean ± 
S.E.M.
Results and Discussion
Neurological phenotype of the PKCγ H101Y transgenic mouse: According to 
our in vitro cell culture study, PKCγ H101Y mutant cells have milder cell 
apoptosis phenotype while S119P and G128D mutants are more severe [4, 6]. 
Therefore, we expected that PKCγ H101Y mutation would not be lethal to the 
transgenic mutant mouse. In the current study, we have successfully created five
PKCγ H101Y transgenic founders as determined by PCR (Fig. 1A, arrowed). We 
also determined the expression of PKCγ H101Y mutant proteins in the transgenic 
cerebellum by immunohistology/confocal microscopy (Fig. 1B). Confocal 
microscopy results demonstrated that endogenous PKCγ is mainly localized in 
Purkinje cells of the wild type C57BL/6J at 4 weeks of age (Fig. 1B, left panel). 
Compared to expression pattern of the wild type of PKCγ, a similar Purkinje cell 
localization of HA-tagged PKCγ H101Y was observed in transgenic mice (Fig. 1B, 
right panel). Of interest, altered Purkinje cell soma were found in the transgenic 
mice at 4 weeks of age (Fig. 1B, arrowed). 
Light microscopy of sections from saggital cerebella of the control and 
PKCγ H101Y transgenic mice is shown in Fig. 1C. As predicted from the cell 
culture studies, transgenic mice overexpressing the PKCγ H101Y SCA14 
mutants were observed with altered morphology of and loss of Purkinje cells at 
four weeks of age (Fig. 1C, right panel). Further, we determined motor function 
using tail suspension photography. In current experiments 11 out of 12, 12-month 
old wild type C57BL/6J mice showed splaying out of hind limbs (Fig. 1D, left 
panel). However, over 90 % of the PKCγ H101Y transgenic mice (11 out of 12 
mice) manifested the stereotypical clasping response (Fig. 1D, right panel) in the 
hind limbs, indicating that the presence of a H101Y SCA14 mutant may confer a 
neurological phenotype which is more severe than a knockout for PKCγ which 
has a normal Purkinje cell layer (data not shown). 
Although the PKCγ H101Y SCA14 transgenic mouse expressed a HA-
tagged SCA14 mutant PKCγ H101Y under CMV promoter control, a universal 
promoter, PKCγ H101Y was expressed specifically in the Purkinje cell layers 
particularly in the soma and dentrites. We chose this promoter after discussion 
with others who had failed to find an effect using a Purkinje cell promoter. We 
have the only colony showing Purkinje neuron degeneration and others are not
currently commercially available.
Dominant negative effect of PKCγ H101Y mutation on wild type 
endogenous PKCγ and Cx57 phosphorylation in the transgenic mice: We 
have previously demonstrated that PKCγ H101Y mutation causes dominant 
negative effects on endogenous wild type PKCγ enzyme activity which leads to 
uncontrolled, open gap junctions in the HT22 cells overexpressing PKCγ SCA14 
mutants [4, 6]. In this study we used HT22 cells and cerebellar slice culture in 
vitro to determine control of Cx57 gap junctions by PKCγ. Almost 90 % 
confluence of HT22 cells were treated with 200 nM TPA or 100 μM H2O2 for 30 
min, cell surface Cx57 gap junction plaques were visualized by 
immunocytochemistry/confocal microscopy as demonstrated previously [4]. 
Plaque number was counted and graphed (Fig. 2A). Results indicated that 
application of PKCγ activators, such as TPA and H2O2, caused decreases in the 
Cx57 gap junction plaques (Fig. 2A, graph). TPA or H2O2-activation of PKCγ
caused Cx57 phosphorylation on serines in HT22 cells as determined by 
immunoprecipation/Western blotting. Inhibition of Cx57 gap junction plaques and 
phosphorylation of Cx57 on serines results in inhibition of gap junction activity. 
Cx57 was newly characterized in the Purkinje cell layers of wild type 
C57BL/6B mouse (Fig. 2B). To determine whether control of Cx57 gap junctions 
was altered in the cerebella of PKCγ transgenic mice, we treated four-week old 
mouse cerebellar slices in culture with 250 μM H2O2 for 30 min and then 
determined Cx57 phosphorylation. As shown in Fig. 2C, PKCγH101Y was only 
expressed in the transgenic mice though endogenous PKCγ were present in both 
types of animals. Lack of Cx57 phosphorylation on serines was observed in the 
transgenic mice. Enzyme activity assay further confirmed that overexpression of 
PKCγ H101Y mutant in vivo caused lack of PKCγ enzyme activity in the 
transgenic cerebella (Fig. 2D). Taken together, overexpression of PKCγ H101Y 
mutants caused malfunction of endogenous wild type PKCγ which may further 
lead to loss of control of gap junctions such as Cx57 in vivo, with or without 
stress stimuli. 
Activation of caspase-12 in the transgenic mouse: Based on the observation 
from cell cultures [6, 7, 18, 33], we next determined endoplasmic reticulum (ER)
stress by activation of caspase-12 in the PKCγ H101Y transgenic mouse. 
Results from Fig. 3 showed that caspase-12 was greatly activated in the PKCγ
H101Y mutant cerebellar tissues. In vitro application of 250 μM H2O2 for 30 min 
significantly enhanced activation of caspase-12, suggesting that ER stress may 
be a key event for phathogenesis of SCA14. 
These data suggest that overexpression of PKCγ SCA14 mutants, e.g., 
H101Y, triggered cellular ER stress and Purkinje cell apoptosis in vivo. Loss of 
control of gap junctions may further propagate ER stress-linked cell death signals 
to adjacent Purkinje cells. This is a novel transgenic mouse model which
provides an important model system to study ER stress-initiated, dysfunction of 
gap junctions-mediated neurodegenerative disorders. This may be a suitable 
model for developing potential treatments that will prevent or delay 
neurodegeneration through restoration of control of gap junction and/or 
elimination of ER stress in the brain.
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Figure Legends
Fig. 1 Characterization of PKCγ H101Y SCA14 transgenic mice A. Five 
founders were identified by PCR using PKCγ H101Y specific primers. Transgenic 
PCR products are arrowed. B. Endogenous PKCγ is mainly localized in Purkinje 
cells of the wild type mouse (left panel), and a similar Purkinje cell localization of 
HA-tagged PKCγ H101Y proteins in the PKCγ H101Y transgenic mouse at the 
age of 4 weeks (right panel). Altered Purkinje cell body is observed in transgenic 
mice (as arrowed). C. Light microscopy of Purkinje cell layers in the wild type (left 
panel) and PKCγ H101Y transgenic mice (right panel) at four weeks of age, 
showing an altered morphology of Purkinje cell layer in the transgenic mice. D.
Tail suspension photography. Almost all 12-month old nontransgenic mice 
demonstrated splaying out of hind limbs (Left panel). However, PKCγ H101Y 
transgenic mice manifested stereotypical clasping responses (Right panel) 
Fig. 2 The dominant negative effect of PKCγ H101Y on Cx57 
phosphorylation and endogenous PKCγ activation in PKCγ H101Y SCA14 
transgenic mice. A. HT22 cells were treated with 200 nM TPA, 100 μM H2O2 , 
or PBS for 30 min, cell surface Cx57 gap junction plaques were measured by 
immunocytochemistry/confocal microscopy. Gap junction plaques per cell were
graphed. Phosphorylation of Cx57 on serines was determined by 
immunoprecipitation/Western blotting (see insert at right). B. Saggittal sections of 
C57BL/6J mouse cerebella at age of 4 weeks were made and endogenous PKCγ 
and Cx57 were labeled and visualized by immunohistology/confocal microscopy. 
C. Four-week old cerebellar slices in culture from the wild type and transgenic 
mice were treated with 250 μM H2O2 for 30 min. After treatments, whole tissue 
extracts were used to determine phosphorylation of Cx57 by Western blotting.
PKCγ H101Y SCA14 mutant proteins are revealed by anti-HA antisera. Total 
cellular PKCγ is revealed by anti-PKCγ antisera. α-tubulin is used as a loading 
control. D. The whole tissue extracts from C were used to immunoprecipitate 
both endogenous PKCγ and HA-tagged PKCγ H101Y by anti-PKCγ antibodies.
The precipitates (wild type and mutant H101Y PKCγ together, see C) were used 
for the enzyme sources to determine total cellular PKCγ enzyme activity. WT= 
control mouse cerebellar slice cultures; H101Y= PKCγ H101Y transgenic mouse 
slices in culture; WT+H101Y= transgenic mouse cerebellar slice cultures which 
have both endogenous PKCγ and the H101Y mutated PKCγ. Note: We can not 
make a quantitative estimate of mutant PKCγ expression vs endogenous wild 
type PKCγ since PKCγ and HA antisera can not be compared to each other.
WB= Western blot
Fig. 3 Activation of caspase-12 in the transgenic mouse. Four-week old 
mouse cerebellar slices in culture were treated with 250 μM H2O2 for 30 min. The 
samples were collected after treatments. The whole tissue extracts were used to 
determine active caspase-3 and caspase-12 by Western blotting. WT= control 
mouse cerebellar slice cultures; H101Y= PKCγ H101Y transgenic mouse slices 
in culture.
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